Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 601–700 of 1,026
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy
Dercle, L., McGale, J., Sun, S. H., Marabelle, A., Yeh, R., Deutsch, É., Mokrane, F., Farwell, M. D., Ammari, S., Schöder, H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005292 · Cited by 109
Pao, W., Ooi, C.-H., Birzele, F., Ruefli-Brasse, A., Cannarile, M. A., Reis, B., Scharf, S. H., Schubert, D. A., Hatje, K., Pelletier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1320 · Cited by 96
Benonisson, H., Altıntaş, I., Sluijter, M., Verploegen, S. A. B. W., Labrijn, A. F., Schuurhuis, D. H., Houtkamp, M., Verbeek, J. S., Schuurman, J., & van Hall, T. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0679 · Cited by 107
“The B16F10 melanoma model is known for its low immune infiltration and can be considered as immunologically cold (37, 49).”
BackgroundPascual, M., Mena-Varas, M., Robles, E. F., Garcia-Barchino, M.-J., Panizo, C., Hervas-Stubbs, S., Alignani, D., Sagardoy, A., Martinez-Ferrandis, J. I., Bunting, K. L., et al. (2019) · Blood · doi:10.1182/blood.2018889931 · Cited by 96
AuNP-Amplified Surface Acoustic Wave Sensor for the Quantification of Exosomes
Wang, C., Wang, C., Jin, D., Yu, Y., Yang, F., Zhang, Y., Yao, Q., & Zhang, G. (2020) · ACS Sensors · doi:10.1021/acssensors.9b01869 · Cited by 96
Li, X., Lu, M., Yuan, M., Ye, J., Zhang, W., Xu, L., Wu, X., Hui, B., Yang, Y., Wei, B., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2118210 · Cited by 106
“Tumors can be divided into 3 different types based on the infiltration of immune cells in the TME: inflammatory, immune excluded and immune desert phenotypes.(33) Evidence shows that immune cells in the TME and intratumoural IFN-γ signaling are more important for tumor prognosis than the TNM staging method in some sol…”
BackgroundXing, S., Hu, K., & Wang, Y. (2022) · Aging and Disease · doi:10.14336/ad.2022.0407 · Cited by 100
“PD-1 (an immune checkpoint receptor) is mainly expressed on exhausted T cells and binds to PDL1 to inhibit signal 2 activation [23, 24].”
BackgroundTurning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 136
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
“tem, determines the priming and activation of effective anti-tumor immunity [36].”
BackgroundLi, Y., He, L., Dong, H., Liu, Y., Wang, K., Li, A., Ren, T., Shi, D., & Li, Y. (2018) · Advanced Science · doi:10.1002/advs.201700805 · Cited by 95
Bhatia, S., Longino, N. V., Miller, N. J., Kulikauskas, R. M., Iyer, J. G., Ibrani, D., Blom, A., Byrd, D. R., Parvathaneni, U., Twitty, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0972 · Cited by 103
“pre-existing cancer-specific immune response (46).”
Hendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 104
“Among them, the tumor should express neoantigens (tumour-specific, mutated peptides presented on the surface of cancer cells) that should be adequately processed and presented by the major histocompatibility complex (MHC) and afterwards these neoantigens should be recognized by T-cells as non-self to achieve an adequa…”
BackgroundMutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Rodriguez-Ruiz, M. E., Rodríguez, I., Mayorga, L., Labiano, T., Barbés, B., Etxeberría, I., Ponz‐Sarvisé, M., Azpilikueta, A., Bolaños, E., Sanmamed, M. F., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0558 · Cited by 99
Sun, R., Sundahl, N., Hecht, M., Putz, F., Lancia, A., Rouyar, A., Milic, M., Carré, A., Battistella, E., Alvarez Andres, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001429 · Cited by 94
Chen, Y., Lv, J., Mao, Y., Li, X., Li, J., Wang, Y., Xu, C., Li, Y., He, Q., Yang, X., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01292-5 · Cited by 100
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 102
“PD-1/PD-L1 axis in the tumor is not the only immunosuppressive pathway (37).”
BackgroundSHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 100
La Fleur, L., Boura, V. F., Alexeyenko, A., Berglund, A., Pontén, V., Mattsson, J. S. M., Djureinovic, D., Persson, J., Brunnström, H., Isaksson, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31545 · Cited by 92
“This finding indicates a population of tumors in our cohort belonging to the “immune-inflamed” subgroup of cancers as reviewed by Chen and Mellman.46 Indeed, a second group of patients displayed overall low expression in the represented immune gene clusters reminiscent of the described “immune desert” subgroup.”
ResultHarnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Vormehr, M., Türeci, Ö., & Sahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 92
Hos, B. J., Camps, M. G. M., van den Bulk, J., Tondini, E., van den Ende, T. C., Ruano, D., Franken, K. L. M. C., Janssen, G. M. C., de Ru, A. H., Filippov, D. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1673125 · Cited by 104
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 101
“The therapeutic benefit or failure to respond to cancer immunotherapies greatly depends on the TME [65,66].”
BackgroundDugage, M. R., Nassif, E. F., Italiano, A., & Bahleda, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775761 · Cited by 106
“For decades, the immuno-oncology concept was thereafter investigated (7, 8) and ICIs have eventually proven only recently to prolong survival in patients with melanoma (9, 10), lung cancer (11, 12), urothelial carcinoma (13) and renal cancer (14), amongst others.”
BackgroundIrreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors
Zhang, N., Li, Z., Han, X., Zhu, Z., Li, Z., Zhao, Y., Liu, Z., & Lv, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811726 · Cited by 113
“From the view of cancer-immune phenotypes (97), IRE can induce an immune-inflamed phenotype”
BackgroundRaufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 112
The impact of the intestinal microbiota in therapeutic responses against cancer
Goubet, A., Daillère, R., Routy, B., Derosa, L., Roberti, P. M., & Zitvogel, L. (2018) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2018.03.004 · Cited by 100
“Prolonged antibiotic treatment with a combination of metronidazole and ciprofloxacine subsequently tripled breast cancer (BC) incidence in proto-oncogene HER2/neu driven-transgenic mice [18].”
BackgroundThe role of the tumour microenvironment in immunotherapy
Gasser, S., Lim, L. H. K., & Cheung, F. S. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0146 · Cited by 103
Jiang, T., Qiao, M., Zhao, C., Li, X., Gao, G., Su, C., Ren, S., & Zhou, C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2126-z · Cited by 100
Zhang, M., Pang, H., Zhao, W., Li, Y., Yan, L., Dong, Z., & He, X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4435-1 · Cited by 102
Yu, S., He, C., & Chen, X. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201800240 · Cited by 95
Chen, L., Oke, T. F., Siegel, N. M., Cojocaru, G., Tam, A. J., Blosser, R. L., Swailes, J., Ligon, J. A., Lebid, A., Morris, C. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3416 · Cited by 96
“Hence, it is imperative to learn about factors influencing the immune set point in sarcomas to determine what druggable targets can be used to mount antitumor immunity (21).”
BackgroundQin, S., Li, Q., Xu, J., Liang, J., Cheng, Y., Fan, Y., Jiang, J., Ye, H., Tao, H., Li, L., et al. (2020) · Cancer Science · doi:10.1111/cas.14641 · Cited by 102
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Liu, Q., Duo, Y., Fu, J., Qiu, M., Sun, Z., Adah, D., Kang, J., Xie, Z., Fan, T., Bao, S., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101023 · Cited by 99
Use of Melatonin in Cancer Treatment: Where Are We?
Wang, L., Wang, C., & Choi, W. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073779 · Cited by 109
“However, the response rate is quite low [106].”
BackgroundCan EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 111
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922867117 · Cited by 91
“Taken together, these observations support the notion that an immune set point, at least in part determined by germline genetic variation, may influence the efficacy of immune checkpoint blockade (1).”
BackgroundSelf-citationHarnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“Furthermore, it is possible that monotherapy acting on a single target is simply insufficient to overcoming the heterogeneous tumor microenvironment (81).”
BackgroundCho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000664 · Cited by 90
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
Zhang, H., Wang, Y., Onuma, A. E., He, J., Wang, H., Xia, Y., Lal, R., Cheng, X., Kasumova, G. G., Hu, Z., et al. (2021) · Cancers · doi:10.3390/cancers13215333 · Cited by 99
Yeh, C. Y., Aguirre, K., Laveroni, O., Kim, S., Wang, A., Liang, B., Zhang, X., Han, L. M., Valbuena, R., Bassik, M. C., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01943-5 · Cited by 103
Chen, X., Wang, L., Li, P., Song, M., Qin, G., Gao, Q., Zhang, Z., Yue, D., Wang, D., Nan, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31730 · Cited by 90
“Partial PD-1 expressing (PD-1) CD8 T cells exhibited a persistent dysfunctional state treated by PD-1/PD-L1 blockade.(9) It was therefore that targeting multiple inhibitory pathways in the TME would be beneficial to the majority of patients with advanced cancers.”
BackgroundMarchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 101
“Despite these successes, it should be stated that only a fraction (10–40%) of treated patients responds positively to checkpoint blockade with PD-1 or PD-L1 specific antibodies (53).”
BackgroundLiao, H., Zhang, Z., Chen, J., Liao, M., Xu, L., Wu, Z., Yuan, K., Song, B., & Zeng, Y. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07815-9 · Cited by 95
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Solinas, C., Aiello, M. M., Rozali, E. N., Lambertini, M., Willard-Gallo, K. E., & Migliori, E. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100811 · Cited by 108
“A new focus of investigation is the role played by stromal cells, which are able to prevent an immune infiltration into tumors [6], representing potential targets that can be manipulated in order to induce more “fighters” (e.”
BackgroundInfluentialImmunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
Brozos-Vázquez, E., Díaz‐Peña, R., García, J., León‐Mateos, L., Mondelo‐Macía, P., Peña-Chilet, M., & López‐López, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02752-z · Cited by 105
Douguet, L., Hreich, S. J. D., Benzaquen, J., Seguin, L., Juhel, T., Dezitter, X., Duranton, C., Ryffel, B., Kanellopoulos, J., Delarasse, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20912-2 · Cited by 106
Xian, D., Niu, L., Zeng, J., & Wang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.653808 · Cited by 94
Zhou, M., Wang, J., Pan, J., Wang, H., Huang, L., Hou, B., Lai, Y., Wang, F., Guan, Q., Wang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39035-x · Cited by 105
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer
Xiong, Y., Wang, Y., & Tiruthani, K. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.102034 · Cited by 89
Leong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 102
Wang, W., Zhong, Y., Zhuang, Z., Xie, J., Lu, Y., Huang, C., Sun, Y., Wu, L. L., Yin, J., Yu, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.253 · Cited by 100
“…JAK/STAT3 signaling pathway is closely related to the formation of inflammatory bowel disease and diverse human solid tumors, including CRC. 47,48 For cycling B cells, stress-related responses including reactive oxygen species pathways, unfolded protein responses, and ultraviolet responses…”
Self-citationA high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients
Li, C., Phoon, Y. P., Karlinsey, K. S., Tian, Y. F., Thapaliya, S., Thongkum, A., Qu, L., Matz, A., Cameron, M. J., Cameron, C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202084 · Cited by 96
Boxberg, M., Steiger, K., Lenze, U., Rechl, H., von Eisenhart-Rothe, R., Wörtler, K., Weichert, W., Langer, R., & Specht, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1389366 · Cited by 87
“© 2018 Taylor & Francis Group, LLC presented on MHC-molecules leading to TC killing mediated particularly by CD8C effector T-cells.8,9,21 Based on the presence or absence of T-cells, the tumor microenvironment (TME) is classified as T-cell inflamed or non T-cell inflamed.6,8 In T-cell inflamed TME, presence of CD8C T-…”
BackgroundThe Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 99
“The cancer−immunity cycle is linked to immunotherapy resistance in another related schema (14).”
BackgroundKamat, A. M., Bellmunt, J., Galsky, M. D., Konety, B. R., Lamm, D. L., Langham, D., Lee, C. T., Milowsky, M. I., O’Donnell, M. A., O’Donnell, P. H., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0271-0 · Cited by 99
“Such agents, which include cytokines, monoclonocal antibodies, immune checkpoint inhibitors, T cell therapies, oncolytic viruses and vaccines, have allowed a subset of patients to benefit from durable response rates, often with a more tolerable adverse event profile than traditional therapies [2].”
BackgroundALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma
Tang, W., Xu, N., Zhou, J., He, Z., Lenahan, C., Wang, C., Ji, H., Liu, B., Zou, Y., Zeng, H., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01286-w · Cited by 97
“Immune checkpoint inhibitors (ICIs) have exhibited remarkable therapeutic success in numerous tumors, placing tumor immunotherapy in the spotlight [4, 5].”
BackgroundLaubli, H. P., Koelzer, V. H., Matter, M. S., Herzig, P., Schlienger, B. D., Wiese, M. N., Lardinois, D., Mertz, K. D., & Zippelius, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386362 · Cited by 92
Echarti, A., Hecht, M., Büttner-Herold, M., Haderlein, M., Hartmann, A., Fietkau, R., & Distel, L. (2019) · Cancers · doi:10.3390/cancers11091398 · Cited by 87
“Besides immune cells, cell surface structures, cytokines, and tumor genetics or the microbiome may be used [6].”
BackgroundInfluentialαvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
Vannini, A., Leoni, V., Barboni, C., Sanapo, M., Zaghini, A., Malatesta, P., Campadelli‐Fiume, G., & Gianni, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901931116 · Cited by 98
“Since cln was administered as an antiangiogenic compound in earlier work, there has been no investigation of its effect on PD-L1 expression and sensitivity to CPIs.”
BackgroundInfluentialAdvancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 99
“The key mechanisms of tumor immunoevasion include: (1) impaired molecular trafficking into the tumor (caused by pro-tumoral endothelium [24,25], altered chemokine profile [26–28], and stiff stroma [29]); (2) microenvironment-mediated alterations that include hyperacidity and increased potassium level [30], presence of…”
BackgroundPutting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Madan, R. A., Antonarakis, E. S., Drake, C. G., Fong, L. H., Yu, E. Y., McNeel, D. G., Lin, D. W., Chang, N. N., Sheikh, N. A., & Gulley, J. L. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa021 · Cited by 95
“In defining tumor types based on their immunity profile, prostate cancer is defined as having an immune-desert phenotype (58).”
BackgroundOvercoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 92
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 92
“Among these, the first and second phenotypes, which are non-inflamed tumors, show a low density of CTLs in the tumors and poor prognosis in immune checkpoint blockade therapy [98].”
BackgroundRecent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy
Zhou, B., Liu, J., Lin, M., Zhu, J., & Chen, W. R. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214009 · Cited by 88
Khan, Z., Hammer, C., Carroll, J., Nucci, F. D., Acosta, S. L., Maiya, V., Bhangale, T., Hunkapiller, J., Mellman, I., Albert, M. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23661-4 · Cited by 93
Self-citationCai, L., Wang, Y., Chen, Y., Chen, H., Yang, T., Zhang, S., Guo, Z., & Wang, X. (2023) · Chemical Science · doi:10.1039/d2sc06036a · Cited by 92
Knopf, P., Stowbur, D., Hoffmann, S. H. L., Hermann, N., Maurer, A., Bucher, V., Poxleitner, M., Tako, B., Sonanini, D., Krishnamachary, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01900-0 · Cited by 106
“Our results suggest that the Several studies suggest a combined immunohistological assessment of PD-L1 expression and tumor-infiltrating lymphocytes to determine IFN-γ-induced PD-L1 expression in the tumor immune microenvironment [62– 64].”
ResultSun, Y., Li, T., Ding, L., Wang, J., Chen, C., Liu, T., Liu, Y., Li, Q., Wang, C., Huo, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000934 · Cited by 105
“[4] Only a small fraction of CTCs survives.”
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 109
“…the response to anti-PD1 or anti-CTLA4 therapies, building on a decade-long pattern of data pointing to the gut microbiome as a critical regulator in the tumour immune microenvironment and the cancer-immune set point (the variable threshold above which an immune response is likely to occur) 39 .”
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Viale, G., Trapani, D., & Curigliano, G. (2017) · BioMed Research International · doi:10.1155/2017/4719194 · Cited by 95
Emerging biomarkers for immune checkpoint inhibition in lung cancer
Cyriac, G., & Gandhi, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.006 · Cited by 89
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
Liu, Z., Ge, Y., Wang, H., Ma, C., Feist, M., Ju, S., Guo, Z. S., & Bartlett, D. L. (2018) · Nature Communications · doi:10.1038/s41467-018-06954-z · Cited by 95
The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis
Troiano, G., Rubini, C., Togni, L., Caponio, V. C. A., Zhurakivska, K., Santarelli, A., Cirillo, N., Muzio, L. L., & Mascitti, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3440 · Cited by 93
Rangamuwa, K., Leong, T., Weeden, C. E., Asselin-Labat, M.-L., Bozinovski, S., Christie, M., John, T., Antippa, P. N., Irving, L. B., & Steinfort, D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1075 · Cited by 95
“This threshold needs to be surpassed for an individual with cancer to respond to immunotherapy (44).”
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Fu, S., Chang, L., Liu, S., Gao, T., Sang, X., Zhang, Z., Mu, W., Liu, X., Liang, S., Yang, H. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38014-6 · Cited by 96
“Immunotherapy has revolutionized antitumour therapy by harnessing thehostimmunesystemtoidentifyandkilltumourcells 1,2 .”
Complex in vitro model: A transformative model in drug development and precision medicine
Wang, L., Hu, D., Xu, J., Hu, J., & Wang, Y. (2024) · Clinical and Translational Science · doi:10.1111/cts.13695 · Cited by 106
“109 Tissue slices and immune co-culture might be optimal choices to reproduce the immune microenvironment in vitro.”
BackgroundTumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 102
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 109
“These tumours are characterized by the inability of TILs to infiltrate into the cancer cell nests and, therefore, are not expected to respond to ICIs 182 .”
Driving cars to the clinic for solid tumors
Castellarin, M. L., Watanabe, K., June, C. H., Kloss, C. C., & Posey, A. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0007-x · Cited by 95
Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.010 · Cited by 85
Ugurel, S., Spassova, I., Wohlfarth, J., Drusio, C., Cherouny, A., Melior, A., Sucker, A., Zimmer, L., Ritter, C., Schadendorf, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02341-9 · Cited by 84
Husain, B., Ramani, S. R., Chiang, E. Y., Lehoux, I. E., Paduchuri, S., Arena, T. A., Patel, A., Wilson, B., Chan, P., Franke, Y., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001433 · Cited by 92
Toyoshima, Y., Kitamura, H., Xiang, H., Ohno, Y., Homma, S., Kawamura, H., Takahashi, N., Kamiyama, T., Tanino, M. A., & Taketomi, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0766 · Cited by 93
“When choosing the optimum therapy for cancer patients, it is important to evaluate their immune status (41).”
BackgroundDai, X., Meng, J., Deng, S., Zhang, L., Wan, C., Lu, L., Huang, J., Hu, Y., Zhang, Z., Li, Y., et al. (2020) · Theranostics · doi:10.7150/thno.42385 · Cited by 87
“An increasing body of evidence indicates that Th1 cells and CTLs play an important role in adaptive antitumor immune responses [35].”
BackgroundPerspective: Designing T-Cell Engagers With Better Therapeutic Windows
Vafa, O., & Trinklein, N. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00446 · Cited by 83
“number of therapeutics (anti-CTLA4, anti-PD-1, and anti-PDL1) were developed to modulate T-cell activation against cancers expressing neoantigens and overcome the immune-suppressive microenvironment of tumors (7, 8).”
BackgroundCancer Vaccines: Antigen Selection Strategy
Zhao, Y., Baldin, A. V., Isayev, O., Werner, J., Zamyatnin, A. A., & Bazhin, A. V. (2021) · Vaccines · doi:10.3390/vaccines9020085 · Cited by 98
“Unlike TAAs, neoantigens exhibit a higher affinity toward MHC molecules due to their “non-self” feature and are more likely to be recognized by T cells [12].”
BackgroundCancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
Ramos, M. I. P., Tian, L., de Ruiter, E. J., Song, C., Paucarmayta, A., Singh, A., Elshof, E., Vijver, S. V., Shaik, J., Bosiacki, J., et al. (2021) · eLife · doi:10.7554/elife.62927 · Cited by 85
“The immune-excluded phenotype is characterized by the presence of immune cells that cannot penetrate the parenchyma of the tumors but instead are located in the stroma that surrounds the tumor cells (Chen and Mellman, 2017).”
BackgroundZhao, P., Tian, Y., Lu, Y., Zhang, J., Tao, A., Xiang, G., & Liu, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01731-z · Cited by 90
“Then these T cells and other immune cells migrate to the tumor site, where promoting continued tumor cell killing and remodeling the tumor microenvironment [6, 7].”
BackgroundLipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
“Inhibiting these checkpoints reactivates the immune system to mount a robust, highly specific response against cancer cells, leading to wide therapeutic success [92, 93].”
BackgroundYu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
“altered amino acid(s) may enable binding of the peptide to a major histocompatibility complex class I molecule, or it may project toward the T-cell antigen receptor.(42)”
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Haratani, K., Yonesaka, K., Takamura, S., Maenishi, O., Kato, R., Takegawa, N., Kawakami, H., Tanaka, K., Hayashi, H., Takeda, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126598 · Cited by 85
“3+ 2 (2) 2+ 7 (8) 1+ 3 (4) 0 6 (7) Not examined 65 (78)”
BackgroundIntegrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Abou Khouzam, R., Goutham, H. V., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaib, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 83
Harnessing Natural Killer Immunity in Metastatic SCLC
Best, S. A., Hess, J. B., Souza-Fonseca-Guimarães, F., Cursons, J., Kersbergen, A. J., Dong, X., Rautela, J., Hyslop, S. R., Ritchie, M. E., Davis, M. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.008 · Cited by 90
Chen, C., Gu, Y., Zhang, F., Zhang, Z.-C., Zhang, Y., He, Y.-D., Wang, L., Zhou, N., Tang, F., Liu, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1901434 · Cited by 93
“The immune system plays an important role in the occurrence and development of cancer.(3) Immunotherapy is a promising tumor treatment method.”
BackgroundImmunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 92
Mazewski, C., Kim, M. S., & de Mejı́a, E. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-47903-0 · Cited by 84
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Loo, K. L., Tsai, K. K., Mahuron, K. M., Liu, J., Pauli, M. L., Sandoval, P. M., Nosrati, A., Lee, J., Chen, L., Hwang, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93433 · Cited by 86
Bretz, A. C., Parnitzke, U., Kronthaler, K., Dreker, T., Bartz, R., Hermann, F., Ammendola, A., Wulff, T., & Hamm, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0745-3 · Cited by 83
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.